Locations:

PDE-5 Inhibitors May Benefit Patients After Centrifugal-Flow LVAD Implant

Outcome benefits from large registry lay groundwork for a randomized controlled trial

21-HVI-2527704-CQD-Hero-2-650×450

Patients with an implanted contemporary centrifugal left ventricular assist device (LVAD) who received phosphodiesterase-5 inhibitor (PDE-5i) therapy after implant had lower rates of death and ischemic stroke than comparable patients not taking a PDE-5i. This finding, from a retrospective analysis of more than 7,000 patients in the national STS (Society of Thoracic Surgeons) Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), was published in JACC: Heart Failure by a team of Cleveland Clinic investigators.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“This study provides intriguing preliminary evidence that adjunctive PDE-5i therapy could provide additional benefits for patients with a contemporary LVAD,” says heart failure cardiologist Randall C. Starling, MD, MPH, the study’s corresponding author. “If these results are confirmed in a randomized controlled trial, we expect that PDE-5i therapy will become standard of care in this setting.”

Mounting evidence of cardiovascular benefit

PDE-5is have multiple effects that, in theory, could improve outcomes for patients with an LVAD. They have antiplatelet and antithrombotic effects, facilitate right ventricle unloading in patients with LVADs and have been shown experimentally to improve right ventricular contractile function.

The PDE-5i sildenafil, which is FDA-approved for erectile dysfunction and pulmonary arterial hypertension, has drawn increasing interest as a possible treatment for cardiovascular disease, with encouraging results. It has not, however, been studied in a randomized controlled trial for patients with an LVAD.

A previous observational study from the current study’s investigators (J Am Heart Assoc. 2020;9[14]:e0158897), based on earlier STS INTERMACS registry data, found fewer thrombotic events and improved survival in patients with an LVAD if they were receiving a PDE-5i. However, that study’s cohort consisted mostly of patients with a HeartMate IITM LVAD, an axial-flow device that is no longer implanted.

Over the years, LVADs have evolved from the first-generation pulsatile-flow devices to continuous-flow devices, including the second-generation (axial flow) and third-generation (centrifugal flow) pumps.

Advertisement

The third-generation HeartMate 3TM is currently the only durable LVAD approved for use in the U.S. Although associated with improved stroke and mortality profiles, it is still associated with a 10% risk of stroke over 24 months and a 75% event-free survival rate at 24 months, leaving room for continued improvements with effective adjunctive therapy.

Study design and results

The current study included 7,229 patients registered in STS INTERMACS between September 2017 and March 2020. All had been implanted with a continuous-flow centrifugal LVAD and had data regarding pharmaceutical treatment. Patients were taking standard anticoagulation and antiplatelet therapies.

The devices were a HeartMate 3 (n = 4,628) and HeartWareTM VAD (n = 2,601). The HeartWare VAD has since been removed from the market by its vendor.

Of the total cohort, 2,173 patients (30.1%) were taking a PDE-5i post-implant. Propensity matching was used to adjust for baseline differences between patients who were and were not taking a PDE-5i. Dr. Starling notes that the use of PDE-5i therapy by patients in the registry is not supported by clinical trial evidence that it improves outcomes in patients with an LVAD and that such therapy is usually given because the patient has pulmonary hypertension.

The primary endpoint — a composite of all-cause mortality, ischemic stroke or pump thrombosis — occurred in:

  • 410 patients (18.9%) in the PDE-5i group
  • 1,071 patients (21.2%) in the non-PDE-5i group

This translates to lower risk for patients taking a PDE-5i (adjusted hazard ratio [HR] = 0.77; 95% CI, 0.69-0.86; P < 0.0001). Results were similar whether patients had received a HeartMate 3 or HeartWare device.

Advertisement

The following were the study’s secondary endpoints:

  • All-cause mortality, which occurred at a lower rate in the PDE-5i group (adjusted HR = 0.75; 95% CI, 0.65-0.86; P < 0.0001)
  • Ischemic stroke, which also occurred at a lower rate in the PDE-5i group (adjusted HR = 0.71; 95% CI, 0.56-0.89; P = 0.003)
  • LVAD thrombosis, with no significant difference between PDE-5i and nonPDE-5i groups and low event rates overall (< 4.0%)

PDE-5i use was associated with increased gastrointestinal bleeding (adjusted HR = 1.18; 95% CI, 1.04-1.34; P = 0.01).

Findings bolster earlier evidence

“This study’s results with the newer LVADs are consistent with findings from our prior study that analyzed patients with the obsolete models,” observes study co-author Edward Soltesz, MD, MPH, Surgical Director of Cleveland Clinic’s Kaufman Center for Heart Failure Treatment and Recovery. “It adds support to the idea that adding PDE-5i therapy merits a randomized clinical trial.”

Although the evidence for benefit of PDE-5i use in patients with a contemporary centrifugal LVAD is growing, the authors note that the study was limited by being a registry-based, nonrandomized, observational study. Furthermore, dosage, type and duration of PDE-5i therapy were unavailable from the registry.

“Cleveland Clinic is actively exploring initiating a multicenter randomized trial for patients with a contemporary LVAD,” Dr. Starling concludes. “This is critical before PDE-5is can be endorsed for this use.”

Advertisement

Related Articles

color echocardiogram with a podcast icon overlay in the middle

Management of Complex Aortic Valve Endocarditis (Podcast)

Medical and surgical perspectives on the condition’s many high-risk scenarios

axial image of the human chest showing the heart and other organs

How Imaging Can Guide Smarter Aortic Valve and Root Decisions

New review proposes a multimodality framework for matching patients to procedures

color cardiac echo next to model of a bulging aorta

Distinctive CME on Valve Imaging and Connective Tissue Disorders on Tap for March 2027

In-depth live symposia in Florida and Cleveland feature interdisciplinary experts from around the nation

yellow and red illustration of blood cells moving through a blood vessel

First-in-Human Data Show One siRNA Can Lower Both LDL-C and Triglycerides

Early results for ARO-DIMER-PA point to a more streamlined way to treat mixed hyperlipidemia

blood vessel on top of a DNA double helix

CRISPR-Cas9 Gene Editing Therapy Safely Slashes Severely Elevated Triglycerides in Early Trial

Findings support further studies of potential one-time treatment strategy

two side-by-side medical illustrations with red trend line overlays

Lipoprotein(a) Reduction With Pelacarsen Has No Impact on Cardiac Events, Lp(a)HORIZON Finds

But unexpected results are ‘not the end of the story’ for Lp(a) lowering, investigators say

stylized heart and lungs with text overlay

Outcome Updates in Adult Cardiac Surgery, Ischemic Heart Disease and Vascular Disease

A scannable snapshot of recent volumes and results

illustration of aortic arch after stent graft repair

Evolving Strategies in Aortic Arch Repair (Podcast)

Earlier detection is reshaping timing and safety of these increasingly common surgeries

Ad